{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:19:39Z","timestamp":1791314379961,"version":"4.3.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"21","license":[{"start":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T00:00:00Z","timestamp":1475539200000},"content-version":"vor","delay-in-days":1142,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1093\/nar\/gkt725","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T22:35:48Z","timestamp":1377038148000},"page":"9634-9650","source":"Crossref","is-referenced-by-count":153,"title":["Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS"],"prefix":"10.1093","volume":"41","author":[{"given":"Michael E.","family":"\u00d8stergaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L.","family":"Southwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Kordasiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels H.","family":"Skotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal N.","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuljeet","family":"Vaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika B.","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E.","family":"Swayze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Frank Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit P.","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,8,19]]},"reference":[{"key":"key\n\t\t\t\t20170512093214_gkt725-B1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrg1691","article-title":"Diseases of unstable repeat expansion: mechanisms and common principles","volume":"6","author":"Gatchel","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrg1829","article-title":"Genetic medicines: treatment strategies for hereditary disorders","volume":"7","author":"O'Connor","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B7","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1038\/sj.emboj.7601445","article-title":"Huntingtin inhibits caspase-3 activation","volume":"25","author":"Zhang","year":"2006","journal-title":"EMBO J."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's Disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat. Genet."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B11","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B12","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for huntington's disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol. Ther."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/mt.2011.185","article-title":"Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease","volume":"19","author":"Boudreau","year":"2011","journal-title":"Mol. Ther."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B14","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.chembiol.2010.10.013","article-title":"Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism","volume":"17","author":"Hu","year":"2010","journal-title":"Chem. Biol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs Use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B18","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts","volume":"19","author":"van Bilsen","year":"2008","journal-title":"Hum. Gene. Ther."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B19","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1371\/journal.pgen.0020140","article-title":"Designing siRNA that distinguish between genes that differ by a single nucleotide","volume":"2","author":"Schwarz","year":"2006","journal-title":"PLoS Genet."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp. Neurol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B21","doi-asserted-by":"crossref","first-page":"19954","DOI":"10.1016\/S0021-9258(19)88650-7","article-title":"Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides","volume":"267","author":"Monia","year":"1992","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B22","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00005072-198809000-00003","article-title":"Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease","volume":"47","author":"de la Monte","year":"1988","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B24","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr. Biol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B25","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1074\/jbc.M210326200","article-title":"Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents","volume":"278","author":"Vickers","year":"2003","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1201\/9780849387951.ch6","volume-title":"Antisense Drug Technology: Principles, Strategies, and Applications","author":"Swayze","year":"2007","edition":"2nd edn"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B28","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/nm1112-1605","article-title":"Getting a fix on SMA","volume":"18","author":"Dolgin","year":"2012","journal-title":"Nat. Med."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/9304","article-title":"Crystal structure and improved antisense properties of 2\u2032-O-(2-methoxyethyl)-RNA","volume":"6","author":"Teplova","year":"1999","journal-title":"Nat. Struct. Biol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2\u2032-4\u2032 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J. Med. Chem."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B31","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/embo-reports\/kvd001","article-title":"The G x U wobble base pair. A fundamental building block of RNA structure crucial to RNA function in diverse biological systems","volume":"1","author":"Varani","year":"2000","journal-title":"EMBO Rep."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B33","doi-asserted-by":"crossref","first-page":"9186","DOI":"10.1021\/ja0157752","article-title":"Long-range cooperativity due to C5-propynylation of oligopyrimidines enhances specific recognition by uridine of ribo-adenosine over ribo-guanosine","volume":"123","author":"Barnes","year":"2001","journal-title":"J. Am. Chem. Soc."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B34","doi-asserted-by":"crossref","first-page":"16655","DOI":"10.1021\/bi991187d","article-title":"Thermodynamics of RNA-RNA duplexes with 2- or 4-thiouridines: implications for antisense design and targeting a group I intron","volume":"38","author":"Testa","year":"1999","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B35","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1021\/ja207086x","article-title":"Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3\u2032-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides","volume":"133","author":"Egli","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B36","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B37","doi-asserted-by":"crossref","first-page":"36317","DOI":"10.1074\/jbc.M405035200","article-title":"Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis","volume":"279","author":"Lima","year":"2004","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.molcel.2007.08.015","article-title":"Structure of human RNase H1 complexed with an RNA\/DNA hybrid: insight into HIV reverse transcription","volume":"28","author":"Nowotny","year":"2007","journal-title":"Mol. Cell"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B39","doi-asserted-by":"crossref","first-page":"28270","DOI":"10.1074\/jbc.274.40.28270","article-title":"Properties of cloned and expressed human RNase H1","volume":"274","author":"Wu","year":"1999","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/mol.106.025015","article-title":"Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate","volume":"71","author":"Lima","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B41","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/jo00109a003","article-title":"5'-Me-DNA - a new oligonucleotide analog: synthesis and biochemical properties","volume":"60","author":"Saha","year":"1995","journal-title":"J. Org. Chem."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B42","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1021\/bi052322r","article-title":"2\u2032-fluoroarabino- and arabinonucleic acid show different conformations, resulting in deviating RNA affinities and processing of their heteroduplexes with RNA by RNase H","volume":"45","author":"Li","year":"2006","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B43","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1021\/bi00230a027","article-title":"Properties of 2'-fluorothymidine-containing oligonucleotides: interaction with restriction endonuclease EcoRV","volume":"30","author":"Williams","year":"1991","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B44","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1039\/c2cc32286b","article-title":"Structure and nuclease resistance of 2\u2032,4\u2032-constrained 2\u2032-O-methoxyethyl (cMOE) and 2\u2032-O-ethyl (cEt) modified DNAs","volume":"48","author":"Pallan","year":"2012","journal-title":"Chem. Commun."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/hmg\/dds397","article-title":"A fully humanized transgenic mouse model of Huntington disease","volume":"22","author":"Southwell","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B46","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington's disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"key":"key\n\t\t\t\t20170512093214_gkt725-B47","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B48","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic Exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170512093214_gkt725-B49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp. Neurol."}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/41\/21\/9634\/16950910\/gkt725.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T05:39:57Z","timestamp":1646372397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article-lookup\/doi\/10.1093\/nar\/gkt725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,19]]},"references-count":49,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2013,8,19]]},"published-print":{"date-parts":[[2013,11]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkt725","relation":{},"ISSN":["1362-4962","0305-1048"],"issn-type":[{"value":"1362-4962","type":"electronic"},{"value":"0305-1048","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8,19]]}}}